Triptolide Prevents Bone Destruction in the Collagen-Induced Arthritis Model of Rheumatoid Arthritis by Targeting RANKL/RANK/OPG Signal Pathway
Figure 4
Triptolide inhibits osteoclast differentiation in CIA mice. Mice were orally administered triptolide (Trip, 8, 16, and 32 μg/kg, resp.), methotrexate (MTX, 0.1 mg/kg), or vehicle for 21 days from the first day of the onset of the clinical symptoms of arthritis. At the end of the experiment, the osteoclast differentiation was evaluated. (a) Tartrate-resistant acid phosphatase (TRAP) stained section from knee joints of vehicle-treated, triptolide-treated, and methotrexate-treated CIA mice. The under graphs is the magnification of the yellow pane in the upper graphs, respectively. (b) The bone destruction score in knee joints of vehicle-treated, triptolide-treated, and methotrexate-treated CIA mice. (c) The number of osteoclasts (multinucleated TRAP positive cells) in knee joints of vehicle-treated, triptolide-treated, and methotrexate-treated CIA mice. Data are represented as the mean ± SD (). , and in comparison with the vehicle control. in comparison with methotrexate-treated CIA mice.
